Page last updated: 2024-12-04

orotic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Orotic Acid: An intermediate product in PYRIMIDINE synthesis which plays a role in chemical conversions between DIHYDROFOLATE and TETRAHYDROFOLATE. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

orotic acid : A pyrimidinemonocarboxylic acid that is uracil bearing a carboxy substituent at position C-6. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID967
CHEMBL ID1235017
CHEBI ID16742
SCHEMBL ID20865
MeSH IDM0015446

Synonyms (138)

Synonym
orotic acid, anhydrous
BB 0242405
2,6-dioxo-1,2,3,6-tetrahydro-pyrimidine-4-ca rboxylic acid
CHEMBL1235017
nsc627082
orotsaeure
CHEBI:16742 ,
2,6-dioxo-1,2,3,6-tetrahydro-pyrimidine-4-carboxylic acid
4-pyrimidinecarboxylic acid, 2,6-dihydroxy-
2,6-dihydroxypyrimidine-4-carboxylic acid
AB-323/25048164
orotic acid (jan)
D00055
orotonsan
orotonin
animal galactose factor
6-uracilcarboxylic acid
2,6-dihydroxy-4-pyrimidinecarboxylic acid
orodin
nsc9791 ,
whey factor
6-carboxyuracil
oropur
orotyl
nsc-9791
oroturic
2,4-dioxo-1h-pyrimidine-6-carboxylic acid
4-pyrimidinecarboxylic acid, 1,2,3,6-tetrahydro-2,6-dioxo-
2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid
inchi=1/c5h4n2o4/c8-3-1-2(4(9)10)6-5(11)7-3/h1h,(h,9,10)(h2,6,7,8,11
ai3-25478
1,2,3,6-tetrahydro-2,6-dioxo-4-pyrimidecarboxylic acid
uracil-6-carbosaeure
4-pyrimidinecarboxylic acid, 1,2,3,6-tetrahydro-2,6-dioxo- (9ci)
1,2,3,6-tetrahydro-2,6-dioxopyrimidin-4-carbonsaeure
ccris 3929
vitamin b13
orotic acid (8ci)
hsdb 6377
NCGC00091357-01
molkensaeure
orotic acid [inn:jan]
orotsaeure [german]
acidum oroticum [latin]
acide orotique [inn-french]
acide orotique [french]
acido orotico [spanish]
nsc 9791
acidum oroticum [inn-latin]
orotic acid (van)
acido orotico [inn-spanish]
einecs 200-619-8
1,2,3,4-tetrahydro-2,6-dioxopyrimidine-4-carboxylic acid
STK301771
orotic acid
65-86-1
C00295
uracil-6-carboxylic acid
orotic acid, >=98% (titration), anhydrous
DB02262
37C71C07-0D69-452C-8C54-7D01BE02C146
orotic acid (van) (8ci)
BMSE000283
O0065
STK629991
AKOS000119689
AKOS004115502
A8909
NCGC00188943-01
NCGC00091357-02
HMS3264K19
61h4t033e5 ,
acidum oroticum
orotic acid [inn:ban:jan]
acide orotique
acido orotico
unii-61h4t033e5
NCGC00258656-01
tox21_201104
BBL013050
61791-00-2
nsc758903
nsc-758903
pharmakon1600-01504525
cas-65-86-1
dtxsid0025814 ,
tox21_111121
dtxcid005814
2,6-dioxo-1,2,3,6-tetrahydro-4-pyrimidinecarboxylic acid
FT-0603612
FT-0648914
NCGC00188943-04
orotic acid [mi]
orotic acid [jan]
orotic acid [mart.]
orotic acid [inn]
orotic acid [inci]
orotic acid [who-dd]
1,2,3,6-tetrahydro-2,6-dioxo-4-pyrimidinecarboxylic acid
orotic acid [hsdb]
S2336
gtpl4690
CCG-213952
HY-N0157
2,6-dihydroxy-pyrimidin-4-carboxylic acid
2,6-dihydroxy-pyrimidine-4-carboxylic acid
SCHEMBL20865
NCGC00188943-03
tox21_111121_1
TS-00078
smr001550463
MLS006011823
orotic-acid-
W-104782
oroticacid
15184-25-5
AB00373897_03
mfcd00006027
F2191-0093
sr-01000872754
SR-01000872754-1
HMS3651I20
orotic acid anhydrous
SBI-0207042.P001
uracil-6-carboxylate
orotsaure
orotic acid(6-carboxyuracil)
SW219707-1
Q425536
orotic acid (6-carboxyuracil)
BCP09063
EN300-16897
SY006030
orotic-acid
AMY4076
D70614
SB55525
orotic acid-15n2

Research Excerpts

Overview

Orotic acid (OA) is a natural product that acts as a precursor in the pyrimidine nucleotide biosynthesis pathway. It is an intermediate in the synthesis pathway of uridine-5'-monophosphate, and increases in body fluids of patients suffering from hereditary disorders such as orotic Aciduria and hyperammonemia.

ExcerptReferenceRelevance
"Orotic acid (OA) is an intermediate of the pyrimidine biosynthesis with high industrial relevance due to its use as precursor for production of biochemical pyrimidines or its use as carrier molecule in drug formulations. "( Orotic acid production by Yarrowia lipolytica under conditions of limited pyrimidine.
Fischer, L; Hetzel, F; Klaiber, I; Pross, E; Seitl, I; Swietalski, P, 2022
)
3.61
"Orotic acid (OA) is a natural product that acts as a precursor in the pyrimidine nucleotide biosynthesis pathway. "( Orotic acid induces apoptotic death in ovarian adult granulosa tumour cells and increases mitochondrial activity in normal ovarian granulosa cells.
Borski, N; Flis, Z; Marynowicz, W; Molik, E; Ptak, A, 2023
)
3.8
"Orotic acid is an intermediate in the biosynthesis pathway of pyrimidine nucleotides and is an indicator for the metabolic cattle disorder deficiency of uridine monophosphate synthase."( Genetic analysis of orotic acid predicted with Fourier transform infrared milk spectra.
Bovenhuis, H; Buitenhuis, AJ; Poulsen, NA; Sundekilde, UK; Zaalberg, RM, 2020
)
1.6
"Orotic acid (OA) is an intermediate of pyrimidine nucleotide biosynthesis. "( Orotic acid induces hypertension associated with impaired endothelial nitric oxide synthesis.
Choi, YJ; Kang, KW; Kang, YP; Kwon, SW; Lee, BH; Lee, KY; Lee, SM; Lim, DK; Yoon, Y, 2015
)
3.3
"Orotic acid is an intermediate in the synthesis pathway of uridine-5'-monophosphate, and increases in body fluids of patients suffering from hereditary disorders such as orotic aciduria and hyperammonemia. "( Sensitive and Selective Determination of Orotic Acid in Biological Specimens Using a Novel Fluorogenic Reaction.
Dragusha, S; Ejupi, V; Kabashima, T; Kai, M; Shibata, T; Yin, S, 2015
)
2.13
"Orotic acid (ORA) is an intermediate metabolite in the pathway of pyrimidine nucleotides; its urinary excretion is useful to diagnose the hereditary orotic aciduria and some hyperammonemic inherited defects of urea cycle enzymes and amino acid transporters. "( Orotic acid quantification in dried blood spots and biological fluids by hydrophilic interaction liquid chromatography tandem mass spectrometry.
Corso, G; D'Apolito, O; Garofalo, D; Paglia, G; Zuppaldi, A, 2010
)
3.25
"Orotic acid (OA) is a tumor promoter of experimental liver carcinogenesis initiated by DNA reactive carcinogens, the molecular mechanisms of which have not been fully elucidated. "( Proliferating effect of orotic acid through mTORC1 activation mediated by negative regulation of AMPK in SK-Hep1 hepatocellular carcinoma cells.
Jung, EJ; Lee, BH; Lee, KY, 2012
)
2.13
"Orotic acid is an important representative of the pyrimidines, the pathophysiological importance of which is less well-known in comparison to the purines. "( [Metabolic effects of orotic acid].
Müller, G, 1984
)
2.02
"Orotic aciduria is a reliable indicator of the function of the urea cycle in lysinuric protein intolerance and facilitates monitoring of the treatment of this disease."( Orotic aciduria in lysinuric protein intolerance: dependence on the urea cycle intermediates.
Rajantie, J, 1981
)
2.43
"Orotic acid (OA) is an intermediate in the pyrimidine pathway. "( Metabolic effect of orotic acid in rat L6 myoblasts.
Blachowski, S; Grzelkowska, K; Kasterka, M; Motyl, T, 1993
)
2.05
"Orotic acid is an important compound in the investigation of several inherited metabolic diseases, and capillary zone electrophoresis provides an effective assay method for this analyte in the clinical laboratory setting. "( Orotic acid in clinical urine specimens by capillary zone electrophoresis using polyvinyl alcohol coated capillaries.
Franke, DR; Nuttall, KL,
)
3.02
"Orotic acid (OA) is an intermediary metabolite of pyrimidine synthesis. "( [Reference values of urinary orotic acid in a healthy Tunisian population].
Ben Hamouda, Y; el Khiari, D; Feki, M; Kaabachi, N; Mebazaa, A; Tebib, N, 1998
)
2.03
"Orotic acid is a precursor of nucleic acids with the ability to enhance protein synthesis."( Sensitivity of the recently infarcted heart to cardioplegic arrest. Beneficial effect of pretreatment with orotic acid.
Chen, XZ; Newman, MA; Rabinov, M; Rosenfeldt, FL; Williams, JF, 1989
)
1.21
"Orotic aciduria is a rare autosomal recessive disease in man due to a deficiency of orotate phosphoribosyltransferase (EC 2.4.2.10; orotidine-5'-phosphate:pyrophosphate phosphoribosyltransferase) and orotidine-5'-phosphate decarboxylase (EC 4.1.1.23; orotidine-5'-phosphate carboxy-lyase). "( Hereditary orotic aciduria: evidence for a structural gene mutation.
Grobner, W; Kelley, WN; Worthy, TE, 1974
)
2.09

Effects

Orotic acid has been given to rats to determine whether blocking the hepatic release of very-low-density lipoproteins would also reduce hepatic secretion of lecithin:cholesterol acyltransferase (LCAT) Orotic Acid has been shown to promote carcinogenesis.

ExcerptReferenceRelevance
"Orotic acid (OA) has been intensively utilized to induce fatty liver in rats. "( Orotic acid-treated hepatocellular carcinoma cells resist steatosis by modification of fatty acid metabolism.
Käkelä, R; Matilainen, J; Mustonen, AM; Nieminen, P; Rilla, K; Sihvo, SP, 2020
)
3.44
"Orotic acid has been given to rats to determine whether blocking the hepatic release of very-low-density lipoproteins would also reduce hepatic secretion of lecithin:cholesterol acyltransferase (LCAT)."( Failure of orotic acid to suppress activity of plasma lecithin:cholesterol acyltransferase.
Miller, JP, 1978
)
1.37
"Orotic acid has been shown to promote carcinogenesis in the liver and the intestine of the rat. "( Inhibition of DNA synthesis in primary cultures of hepatocytes by orotic acid.
Laconi, E; Li, F; Rajalakshmi, S; Rao, PM; Sarma, DS; Semple, E, 1988
)
1.95

Actions

ExcerptReferenceRelevance
"Orotic acid is known to cause fatty liver, but it is unclear whether this is caused partly by stimulation of the enzymes for triacylglycerol (TG) synthesis. "( Association between hepatic triacylglycerol accumulation induced by administering orotic acid and enhanced phosphatidate phosphohydrolase activity in rats.
Cha, JY; Mameda, Y; Oogami, K; Yamamoto, K; Yanagita, T, 1998
)
1.97

Treatment

Orotic acid treatment significantly improved post-ischaemic myocardial function. Treatment with orotic Acid produced a further upward trend in uridine nucleotide levels.

ExcerptReferenceRelevance
"Both orotic acid-treated and untreated hearts manifested decreased expression of the beta-myosin heavy chain protein and steady-state messenger RNA levels."( Orotic acid improves left ventricular recovery four days after heterotopic transplantation.
Dignan, RJ; Dyke, CM; Jakoi, ER; Johnson, DE; Rebeyka, IM; Wechsler, AS; Yeh, T, 1994
)
2.19
"Orotic acid treatment significantly improved post-ischaemic myocardial function and increased pre-ischaemic and post-ischaemic glycogen content of the heart."( Effects of orotic acid on ischaemic/reperfused myocardial function and glycogen content in isolated working rat hearts.
Fazekas, T; Ferdinandy, P; Kádár, E, 1998
)
1.41
"Treatment with orotic acid produced a further upward trend in uridine nucleotide levels."( The effect of orotic acid on the response of the recently infarcted rat heart to hypothermic cardioplegia.
Conyers, RA; Langley, LH; Munsch, CM; O'Halloran, K; Rosenfeldt, FL; Williams, JF, 1991
)
0.98

Toxicity

ExcerptReferenceRelevance
" These acute toxic effects of aflatoxin B1 were partially decreased by an addition of 4 X 10(-5) M estradiol-17 beta."( Prevention by estradiol of aflatoxin-induced cytotoxicity in cultured chick embryo liver cells.
Kurebe, M; Nishiyama, S, 1981
)
0.26
" We speculate that 5-FU cytotoxic effects, both anti-tumor effects and adverse reactions, would be weak when a patient with hereditary orotic aciduria was treated with 5-FU."( Decreased fluorouracil cytotoxic effect on EB-virus transformed lymphocytes from hereditary orotic aciduria.
Andou, M; Sumi, S; Togari, H; Wada, Y, 2000
)
0.73
" Zinc-citrate and zinc-sulphate turned out to be the most toxic salts particularly at low concentrations."( Comparative in vitro toxicity of seven zinc-salts towards neuronal PC12 cells.
Gaunitz, F; Gebhardt, R; Pavlica, S, 2009
)
0.35

Pharmacokinetics

ExcerptReferenceRelevance
" The plasma concentration curve for zinc orotate shows a faster distribution (alpha) and elimination phase (beta) after parenteral administration, and a slower absorption phase (Ka) after oral administration, when compared with that of the other two salts."( The bioavailability and pharmacokinetics of three zinc salts: zinc pantothenate, zinc sulfate and zinc orotate.
Andermann, G; Dietz, M, 1982
)
0.26
" This study aims to evaluate the possible pharmacokinetic changes in NAFLD as a result of reduced metabolic activity of CYP2D."( Effects of Orotic Acid-Induced Non-Alcoholic Fatty Liver on the Pharmacokinetics of Metoprolol and its Metabolites in Rats.
Bang, WS; Hwang, YR; Kang, HE; Lee, I; Li, Z, 2019
)
0.9

Compound-Compound Interactions

Fluoroorotic acid (FOA) alone and in combination with irinotecan (IRN) were encapsulated in liposomes and evaluated for their anti-tumor activity in the C26 colon carcinoma mouse model.

ExcerptReferenceRelevance
"Analysis of the dynamics of changes in the end part of the ECG ventricular complex in 311 patients with rheumatic heart disease and stages IIA, IIB, and III circulatory insufficiency after treatment with preparations of digitalis and their combination with biologically active substances (orotic acid, vitamin B12, calcium pantothenate, ATP, methionine, inosi-F) is presented."( [Changes in the end part of the ECG ventricular complex under the effect of digitalis preparations and their combination with metabolic preparations].
Abbakumov, SA; Makolkin, VI; Masliuk, VI; Nedostup, AV; Popova, TA, 1977
)
0.43
"To test the hypothesis that co-delivery of synergistic drug combinations in the same liposome provides a better anti-tumor effect than the drugs administered in separate liposomes, fluoroorotic acid (FOA) alone and in combination with irinotecan (IRN) were encapsulated in liposomes and evaluated for their anti-tumor activity in the C26 colon carcinoma mouse model."( Anti-tumor activity of liposome encapsulated fluoroorotic acid as a single agent and in combination with liposome irinotecan.
Jerger, K; Kieler-Ferguson, HM; Riviere, K; Szoka, FC, 2011
)
0.81
"To study neocollagenogenesis after implantation of polypropylene endoprosthesis and polypropylene combined with polylactic acid endoprosthesis on background of «potassium orotate» administration."( [The influence of 'potassium orotate' on neocollagenogenesis in implantation of polypropylene endoprosthesis and polypropylene combined with polylactic acid endoprosthesis].
Ivanov, IS; Ivanov, SV; Lazarenko, VA; Ob''edkov, EG; Parfenov, IP; Tarabrin, DV; Tsukanov, AV,
)
0.13
" The first type was made of just polypropylene, the second type was made of polypropylene combined with polylactic acid."( [The influence of 'potassium orotate' on neocollagenogenesis in implantation of polypropylene endoprosthesis and polypropylene combined with polylactic acid endoprosthesis].
Ivanov, IS; Ivanov, SV; Lazarenko, VA; Ob''edkov, EG; Parfenov, IP; Tarabrin, DV; Tsukanov, AV,
)
0.13

Bioavailability

ExcerptReferenceRelevance
" Since these phenomena were not associated with enhanced biosynthesis of orotate de novo, the increased glomerular UDP-sugar bioavailability in diabetes is due to enhanced utilization of exogenous orotate."( Glomerular uracil nucleotide synthesis: effects of diabetes and protein intake.
Cortes, P; Dumler, F; Levin, NW; Paielli, DL, 1988
)
0.27
" Studies were designed to assess the bioavailability of 5-phosphoribosyl-1-pyrophosphate (PRPP) in the diabetic renal cortex because PRPP is an important determinant of the de novo synthesis of nucleotides."( Phosphoribosylpyrophosphate bioavailability in diabetic rat renal cortex in vivo.
Cortes, P; Levin, NW; Schoenberger, AM; Venkatachalam, KK; Verghese, CP, 1980
)
0.26
" Carboxyamidotriazole-orotate (CTO) is the orotate salt form of carboxyamidotriazole (CAI), an orally bioavailable signal transduction inhibitor that in vitro has been shown to possess antileukaemic activities."( Carboxyamidotriazole-orotate inhibits the growth of imatinib-resistant chronic myeloid leukaemia cells and modulates exosomes-stimulated angiogenesis.
Alessandro, R; Corrado, C; De Leo, G; Flugy, AM; Guggino, G; Karmali, R; Raimondo, S; Taverna, S, 2012
)
0.38
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Liver and kidney samples were also taken at appropriate times after dosing and examined histologically for evidence of drug induced damage."( Young Scientists Award Lecture 1977: An investigation into the value of some clinical biochemical tests in the detection of minimal changes in liver morphology and function in the rat.
Clampitt, RB, 1978
)
0.26
" Injection of protein or glycoprotein precursors into one Rc produced heavy labeling of both Rcs including their processes; a slight labeling of other ganglion compartments was only found after increasing the dosage of the amino acids glycine and leucine."( Transfer of radioactive material between electrically coupled neurons of the leech central nervous system.
Kreutzberg, GW; Rieske, E; Schubert, P, 1975
)
0.25
"The present study was carried out to investigate the time course of metabolization in brain and the influence on RNA synthesis of a retention-improving dosage of methylglucamine orotate after intracerebroventricular application."( Metabolization of a retention-improving dosage of methylglucamine orotate in rat brain.
Matthies, H; Popov, N; Staak, S; Tischmeyer, W, 1990
)
0.28
" In the N3 nitrogen-substituted series one compound, 5,5-diphenyl-N3-n-butyl-2-thiohydantoin, DPBTH (7), showed promise during initial screening, but when analyzed in a dose-response study, its activity was considerably less than that of the parent compound DPTH."( 5,5-Diaryl-2-thiohydantoins and 5,5-diaryl-N3-substituted-2-thiohydantoins as potential hypolipidemic agents.
Tompkins, JE, 1986
)
0.27
" FOA in different dosage forms was applied topically 2 to 3 times daily for 30 days."( Studies on the antimycotic activity of 5-fluoroorotic acid.
Golovinsky, E; Karamanov, G; Maneva, L; Nikolova, K, 1987
)
0.53
" A time-response and a dose-response study showed that actinomycin D inhibits pulmonary RNA synthesis as efficiently as hepatic RNA synthesis."( Qualitative and quantitative aspects of the biosynthesis of ribonucleic acid and of protein in the liver and the lung of the Syrian golden hamster.
Witschi, H, 1973
)
0.25
" A half-life of 5 days was obtained and this was not affected by injecting animals with unlabelled methyl methanesulphonate at the same dosage of 50mg/kg used in the studies of RNA methylation."( The stability of rat liver ribonucleic acid in vivo after methylation with methyl methanesulphonate or dimethylnitrosamine.
Craig, AW; McElhone, MJ; O'Connor, PJ, 1971
)
0.25
" Although the uridine dosage (0."( Purine and pyrimidine metabolism in hereditary orotic aciduria: some unexpected effects of allopurinol.
Becroft, DM; Potter, CF; Simmonds, HA; Webster, DR, 1980
)
0.52
" High doses of PALA (1 to 2 g/sq m) prevented the use of full dosage of FUra; however, PALA (250 mg/sq m) can be administered 24 hr before FUra (750 mg/sq m) once weekly for at least 3 weeks."( Phase I and clinical pharmacological evaluation of biochemical modulation of 5-fluorouracil with N-(phosphonacetyl)-L-aspartic acid.
Casper, ES; Martin, DS; Vale, K; Williams, LJ; Young, CW, 1983
)
0.27
"Most concentrations of OA used in this study did not induce HL in cats during a 29-day period, but the highest dosage used did result in renal disease."( Effects of oral administration of orotic acid on hepatic morphologic characteristics and serum biochemical variables in cats.
Dimski, DS; Hosgood, G; Swenson, DH; Taboada, J; Taylor, HW; VanSteenhouse, JL, 1999
)
0.58
" To study the effects of PSC on liver cancer development, a daily dose of 30 mg PSC/kg body wt (PSC30) was chosen based on an initial dose-response experiment."( Effect of PSC 833, an inhibitor of P-glycoprotein, on 1,2-dimethylhydrazine-induced liver carcinogenesis in rats.
Bradley, G; Kankesan, J; Laconi, E; Ling, V; Rajalakshmi, S; Rao, PM; Sarma, DS; Thiessen, JJ; Vanama, R; Yusuf, A, 2003
)
0.32
" The results obtained indicate that the tested compounds exerted a considerable cytotoxic activity upon the evaluated cell lines in a concentration-dependent matter, which enabled the construction of dose-response curves and the calculation of the corresponding IC(50 )values."( New lanthanum (III) complex--synthesis, characterization, and cytotoxic activity.
Kiefer, W; Kostova, I; Kostovski, A; Rastogi, VK, 2006
)
0.33
" The study was conducted in 60 volunteers, who once took oral dosing of magnesium -bearing preparation "Magnerot" (500 mg of magnesium orotat converting to Mg2+ 32,8 Mg) and "Centrum" (100 mg of magnesium oxide converting to Mg2+ - 60,3 Vg) or vitamins B1 and B2 in 10, 20 and 30 mg doses."( [The results of application of magnesium-bearing medications and different load doses of vitamins B1 and B2 in volunteers].
Koniukhova, OS; Krasnykh, LI; Shikh, EV, 2006
)
0.33
" Lipid deposition in livers of patients with the metabolic syndrome may necessitate dosage adjustments for toxic drugs, including CLZ."( Impaired microsomal oxidation of the atypical antipsychotic agent clozapine in hepatic steatosis.
Murray, M; Ramzan, I; Zhang, WV, 2007
)
0.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
pyrimidinemonocarboxylic acid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (11)

PathwayProteinsCompounds
Pyrimidine Metabolism2353
beta-Ureidopropionase Deficiency2353
UMP Synthase Deficiency (Orotic Aciduria)2353
Dihydropyrimidinase Deficiency2353
MNGIE (Mitochondrial Neurogastrointestinal Encephalopathy)2353
5'-Orotidylic acid + Pyrophosphate = Orotic acid + D-5-Phospho-ribosyl 1-diphosphate ( Pyrimidine Nucleotides and Nucleosides metabolism )14
Pyrimidine Nucleotides and Nucleosides metabolism ( Pyrimidine Nucleotides and Nucleosides metabolism )4549
(S)-Dihydro-orotic acid + O2 = Orotic acid + H2O2 ( Pyrimidine Nucleotides and Nucleosides metabolism )14
Biomarkers for urea cycle disorders1222
Biochemical pathways: part I0466
Pyrimidine metabolism038
De novo synthesis of UMP221

Protein Targets (16)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
phosphopantetheinyl transferaseBacillus subtilisPotency39.81070.141337.9142100.0000AID1490
RAR-related orphan receptor gammaMus musculus (house mouse)Potency0.21710.006038.004119,952.5996AID1159521
GLI family zinc finger 3Homo sapiens (human)Potency13.33320.000714.592883.7951AID1259369; AID1259392
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency18.83360.000657.913322,387.1992AID1259378
progesterone receptorHomo sapiens (human)Potency23.71010.000417.946075.1148AID1346795
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency26.83250.000214.376460.0339AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency42.09220.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency0.30110.000817.505159.3239AID1159527
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency22.71840.001530.607315,848.9004AID1224848; AID1224849
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency39.81070.001019.414170.9645AID588537
activating transcription factor 6Homo sapiens (human)Potency7.56240.143427.612159.8106AID1159516
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency18.99590.057821.109761.2679AID1159526; AID1159528
heat shock protein beta-1Homo sapiens (human)Potency25.94290.042027.378961.6448AID743210; AID743228
lamin isoform A-delta10Homo sapiens (human)Potency1.25890.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 2, facilitated glucose transporter member 9Homo sapiens (human)IC50 (µMol)1,000.0000300.0000650.00001,000.0000AID1794831
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (7)

Processvia Protein(s)Taxonomy
hexose transmembrane transportSolute carrier family 2, facilitated glucose transporter member 9Homo sapiens (human)
urate transportSolute carrier family 2, facilitated glucose transporter member 9Homo sapiens (human)
fructose transmembrane transportSolute carrier family 2, facilitated glucose transporter member 9Homo sapiens (human)
urate metabolic processSolute carrier family 2, facilitated glucose transporter member 9Homo sapiens (human)
proton transmembrane transportSolute carrier family 2, facilitated glucose transporter member 9Homo sapiens (human)
glucose transmembrane transportSolute carrier family 2, facilitated glucose transporter member 9Homo sapiens (human)
monosaccharide transmembrane transportSolute carrier family 2, facilitated glucose transporter member 9Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
carbohydrate:proton symporter activitySolute carrier family 2, facilitated glucose transporter member 9Homo sapiens (human)
fructose transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 9Homo sapiens (human)
glucose transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 9Homo sapiens (human)
urate transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 9Homo sapiens (human)
transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 9Homo sapiens (human)
hexose transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 9Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
plasma membraneSolute carrier family 2, facilitated glucose transporter member 9Homo sapiens (human)
membraneSolute carrier family 2, facilitated glucose transporter member 9Homo sapiens (human)
basolateral plasma membraneSolute carrier family 2, facilitated glucose transporter member 9Homo sapiens (human)
apical plasma membraneSolute carrier family 2, facilitated glucose transporter member 9Homo sapiens (human)
plasma membraneSolute carrier family 2, facilitated glucose transporter member 9Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (46)

Assay IDTitleYearJournalArticle
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1417100Binding affinity to Leishmania major DHODH assessed as change in melting temperature at 1000 uM by SYPRO orange dye-based differential scanning fluorimetry2018European journal of medicinal chemistry, Sep-05, Volume: 157Natural products as inhibitors of Leishmania major dihydroorotate dehydrogenase.
AID1417099Binding affinity to Leishmania major DHODH assessed as change in melting temperature at 500 uM by SYPRO orange dye-based differential scanning fluorimetry2018European journal of medicinal chemistry, Sep-05, Volume: 157Natural products as inhibitors of Leishmania major dihydroorotate dehydrogenase.
AID603957Octanol-water partition coefficient, log P of the compound2008European journal of medicinal chemistry, Apr, Volume: 43, Issue:4
QSPR modeling of octanol/water partition coefficient for vitamins by optimal descriptors calculated with SMILES.
AID1417095Binding affinity to Leishmania major DHODH assessed as change in melting temperature at 100 uM by differential scanning fluorimetry-based ThermoFMN assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Natural products as inhibitors of Leishmania major dihydroorotate dehydrogenase.
AID1417097Binding affinity to Leishmania major DHODH assessed as change in melting temperature at 1000 uM by differential scanning fluorimetry-based ThermoFMN assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Natural products as inhibitors of Leishmania major dihydroorotate dehydrogenase.
AID1417098Binding affinity to Leishmania major DHODH assessed as change in melting temperature at 100 uM by SYPRO orange dye-based differential scanning fluorimetry2018European journal of medicinal chemistry, Sep-05, Volume: 157Natural products as inhibitors of Leishmania major dihydroorotate dehydrogenase.
AID1417096Binding affinity to Leishmania major DHODH assessed as change in melting temperature at 500 uM by differential scanning fluorimetry-based ThermoFMN assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Natural products as inhibitors of Leishmania major dihydroorotate dehydrogenase.
AID545994Inhibition of Trypanosoma cruzi dihydroorotate dehydrogenase by isothermal titration calorimetry2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Novel insights for dihydroorotate dehydrogenase class 1A inhibitors discovery.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (3,166)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902495 (78.81)18.7374
1990's272 (8.59)18.2507
2000's212 (6.70)29.6817
2010's145 (4.58)24.3611
2020's42 (1.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 40.98

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index40.98 (24.57)
Research Supply Index8.14 (2.92)
Research Growth Index4.27 (4.65)
Search Engine Demand Index100.26 (26.88)
Search Engine Supply Index2.95 (0.95)

This Compound (40.98)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials53 (1.57%)5.53%
Reviews103 (3.04%)6.00%
Case Studies76 (2.24%)4.05%
Observational1 (0.03%)0.25%
Other3,153 (93.12%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]